Moleculin Biotech, Inc.
Moleculin Biotech, Inc. logo
MBRX

Moleculin Biotech, Inc. (MBRX)

$1.260.79%

Market is closed
– opens on 8 PM, 31 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$1.25
Day's Range
$1.2999
$0.817
52-Week Range
$2.05
1 month return17.76%
3 month return26.0%
1 year return16.56%
5 year return88.83%

Analyst Recommendation

based on 9 analysts ratings

Buy
88%
Buy
11%
Hold
0%
Sell

Based on 9 Wall street analysts offering stock ratings for Moleculin Biotech, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 588.1%

Current

$1.26

Target

$8.67

Recommendation Trend

Based on 9 analyst

Current1M Ago3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization36.5M
Book Value$2.04
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-0.64
PEG Ratio0.0
Wall Street Target Price8.67

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)0.66
Enterprise Value-11267434
Enterprise Value/Revenue0.0
Enterprise Value/Ebitda0.39

Technicals

Beta1.96
50 Day MA1.26
200 Day MA1.38

Institutional Holdings

Vanguard Group Inc

3.77%

Sio Capital Management, LLC

3.62%

BlackRock Inc

0.92%

Geode Capital Management, LLC

0.86%

Renaissance Technologies Corp

0.3%

State Street Corporation

0.25%

Company Information

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a NextGeneration Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.
OrganizationMoleculin Biotech, Inc.
Employees13
CEOMr. Walter V. Klemp
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Moleculin Biotech, Inc. share price today?

Can Indians buy Moleculin Biotech, Inc. shares?

How can I buy Moleculin Biotech, Inc. shares from India?

Can Fractional shares of Moleculin Biotech, Inc. be purchased?

What are the documents required to start investing in Moleculin Biotech, Inc. stocks?

What are today’s High and Low prices of Moleculin Biotech, Inc.?

What are today’s traded volumes of Moleculin Biotech, Inc.?

What is today’s market capitalisation of Moleculin Biotech, Inc.?

What is the 52 Week High and Low Range of Moleculin Biotech, Inc.?

How much percentage Moleculin Biotech, Inc. is down from its 52 Week High?

How much percentage Moleculin Biotech, Inc. is up from its 52 Week low?

What are the historical returns of Moleculin Biotech, Inc.?

Who is the Chief Executive Officer (CEO) of Moleculin Biotech, Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*